Table I. Anti-phospholipid monoclonal... | Rockefeller University Press

Table I.

Anti-phospholipid monoclonal antibodies in this study

mAb	Heavy chain	Light chain	Binds cardiolipin/PS	Binds HIV-1 Env	Binds directly to β₂GP1	Binding to CL/PS dependent on β₂GP1	mAb origin
IS4	γ3 VH1	λ Vλ2	++	−	+	Yes	APS subject
CL1	γ3 VH1	λ Vλ3	++	−	++	No	SLE subject with APS
P1	γ1	λ	++	−	+++	No	SLE subject with APS
PGN632	γ1	λ	++	−	+	No	uninfected and healthy subject^a
PGN401	γ1	κ	+	−	+	Yes	humanized mouse mAb
B1	γ1	κ	+	−	+++	Yes	APS subject
B2	γ3	κ	++	−	+	Yes	APS subject
PGN635	γ1	λ	+	−	+	Yes	uninfected and healthy subject^a
PGN634	γ1	λ	+	−	+	Yes	uninfected and healthy subject^a
2F5	γ3	κ	+	+	+	No	HIV-1 + subject
4E10	γ3	κ	+	+	+	No	HIV-1 + subject

mAb	Heavy chain	Light chain	Binds cardiolipin/PS	Binds HIV-1 Env	Binds directly to β₂GP1	Binding to CL/PS dependent on β₂GP1	mAb origin
IS4	γ3 VH1	λ Vλ2	++	−	+	Yes	APS subject
CL1	γ3 VH1	λ Vλ3	++	−	++	No	SLE subject with APS
P1	γ1	λ	++	−	+++	No	SLE subject with APS
PGN632	γ1	λ	++	−	+	No	uninfected and healthy subjecta
PGN401	γ1	κ	+	−	+	Yes	humanized mouse mAb
B1	γ1	κ	+	−	+++	Yes	APS subject
B2	γ3	κ	++	−	+	Yes	APS subject
PGN635	γ1	λ	+	−	+	Yes	uninfected and healthy subjecta
PGN634	γ1	λ	+	−	+	Yes	uninfected and healthy subjecta
2F5	γ3	κ	+	+	+	No	HIV-1 + subject
4E10	γ3	κ	+	+	+	No	HIV-1 + subject

Derived from an antibody library from normal subjects. PGN632 was further engineered to optimize binding to PS.